Skip to main content
SpringerLink
Log in

Olmesartan medoxomil: a guide to its use in hypertension

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68(9): 1239–72

    Article  PubMed  CAS  Google Scholar 

  2. Olmetec film-coated tablets; summary of product characteristics. Gerrards Cross: Daiichi Sankyo UK Limited, 2007 Aug

  3. Benicar® tablets (olmesartan medoxomil): US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2007 Jul

  4. Benicar HCT® tablets (olmesartan medoxomil-hydrochlorothiazide): US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2007 Jul

  5. Olmetec Plus film-coated tablets; summary of product characteristics. Gerrards Cross: Daiichi Sankyo UK Limited, 2006 Aug

  6. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001; 41(5): 515–27

    Article  PubMed  CAS  Google Scholar 

  7. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285(2): 181–8

    Article  PubMed  CAS  Google Scholar 

  8. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001; 19Suppl. 1: 21–32

    Google Scholar 

  9. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001; 19Suppl. 1: 15–20

    Google Scholar 

  10. Neutel JM, Elliott WJ, Izzo Jr JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002; 4(5): 325–31

    Article  CAS  Google Scholar 

  11. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19Suppl. 1: 49–56

    Google Scholar 

  12. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3(5): 283–91

    Article  CAS  Google Scholar 

  13. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens 2007; 9(3): 187–95

    Article  CAS  Google Scholar 

  14. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23(7): 419–30

    Article  CAS  Google Scholar 

  15. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17(6): 425–32

    Article  PubMed  CAS  Google Scholar 

  16. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16Suppl. 2: 24–8

    Article  Google Scholar 

  17. Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag 2006; 2(4): 327–40

    Article  PubMed  CAS  Google Scholar 

  18. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig 2007; 27(8): 545–58

    Article  PubMed  CAS  Google Scholar 

  19. Rump LC, Ambrosioni E, Burnier M, et al. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension [letter]. J Hum Hypertens 2006; 20(4): 299–301

    Article  PubMed  CAS  Google Scholar 

  20. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7(5): 361–72

    Article  PubMed  CAS  Google Scholar 

  21. Heagerty AM, Mallion J-M. Effect of age on olmesartan medoxomil plus hydrochlorothiazide [abstract no. P-72 MP-38]. J Clin Hypertens 2007; 9(5 Suppl. A): 34–5

    Google Scholar 

  22. Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 2007; 9(1): 36–44

    Article  CAS  Google Scholar 

  23. Mallion J-M, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25(10): 2168–77

    Article  PubMed  CAS  Google Scholar 

  24. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87 Suppl. 8A: 37–43

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olmesartan medoxomil: a guide to its use in hypertension. Drugs Ther. Perspect 25, 5–9 (2009). https://doi.org/10.2165/0042310-200925010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925010-00002

Search

Navigation